Modern management of colorectal cancer--a pathologist's view.
Colorectal cancer is an increasingly significant cause of both mortality and morbidity due to wider adoption of the Western lifestyle and a progressively ageing population. Recently steps forward have been made both in surgical and chemoradiotherapeutic management of this disease. Well performed total mesorectal excision surgery has now become the gold standard for rectal cancer resection. Several prognostic markers, both clinicopathological and molecular, have been identified allowing better patient counselling and targeting of treatment. The rationale for patient selection, timing and dose of radiotherapy has been further elucidated. New chemotherapy agents are under trial and predictive factors allowing selection of those patients most likely to respond to them have been identified. Many of these factors will increase in importance as colorectal cancer becomes a chronic disease with lengthening survival times. As we will discuss the pathologist has important roles in all of these developments and at all stages of colorectal cancer management.
Maughan
N J
NJ
Academic Unit of Pathology, University of Leeds, Leeds, UK. nicmaughan@hotmail.com
Quirke
P
P
D015179:Colorectal Neoplasms / Q000235:genetics / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D004268:DNA-Binding Proteins / Q000235:genetics; D006801:Humans; D009367:Neoplasm Staging; D011379:Prognosis; D012042:Registries; D051901:Smad4 Protein; D015534:Trans-Activators / Q000235:genetics
D004268:DNA-Binding Proteins; C497796:SMAD4 protein, human; D051901:Smad4 Protein; D015534:Trans-Activators